* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Regulation, Reimbursement, and the Long Road of
Survey
Document related concepts
Drug interaction wikipedia , lookup
Drug design wikipedia , lookup
National Institute for Health and Care Excellence wikipedia , lookup
Drug discovery wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Clinical trial wikipedia , lookup
Pharmacognosy wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Prescription costs wikipedia , lookup
Theralizumab wikipedia , lookup
Transcript
VALUE IN HEALTH 16 (2013) S27–S31 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Regulation, Reimbursement, and the Long Road of Implementation of Personalized Medicine—A Perspective from the United States Felix W. Frueh, PhD* Opus Three LLC, Gaithersburg, MD, USA AB STR A CT There is undisputed evidence that personalized medicine, that is, a more precise assessment of which medical intervention might best serve an individual patient on the basis of novel technology, such as molecular profiling, can have a significant impact on clinical outcomes. The field, however, is still new, and the demonstration of improved effectiveness compared with standard of care comes at a cost. How can we be sure that personalized medicine indeed provides a measurable clinical benefit, that we will be able to afford it, and that we can provide adequate access? The risk-benefit evaluation that accompanies each medical decision requires not only good clinical data but also an assessment of cost and infrastructure needed to provide access to technology. Several examples from the last decade illustrate which types of personalized medicines and diagnostic tests are easily being taken up in clinical practice and which types are more difficult to introduce. And as regulators and payers in the United States and elsewhere are taking on personalized medicine, an interesting convergence can be observed: better, more complete information for both approval and coverage decisions could be gained from a coordination of regulatory and reimbursement questions. Health economics and outcomes research (HEOR) emerges as an approach that can satisfy both needs. Although HEOR represents a well-established approach to demonstrate the effectiveness of interventions in many areas of medical practice, few HEOR studies exist in the field of personalized medicine today. It is reasonable to expect that this will change over the next few years. Keywords: health economics, outcomes research, personalized medicine, regulatory, reimbursement. A brief search in PubMed [1] for “personalized medicine” reveals 10,249 hits, a search for “health economics and outcomes research” reveals 15,409 hits, and a combination of both search terms reveals a mere 48 hits. By combining “personalized medicine” with “economics,” one finds 519 articles; by combining “personalized medicine” with “outcomes,” one finds 989 articles. Clearly, the intersection of personalized medicine with outcomeor economic-oriented research is poorly investigated. Also, the increase (as small as the sample size may be) during the last 3 years is interesting: 5 articles in 2009, 6 in 2010, and 12 in 2011 compared with an average of 1 per year for the last decade. Have we just realized that outcomes and cost matter for the implementation of personalized medicine? Ten years ago, Lesko and Woodcock [2] described in a seminal article how the Food and Drug Administration (FDA) envisions pharmacogenetics to help guide drug development: it was becoming increasingly apparent that the regulatory body will get exposed to such information and that a regulatory path needs to be developed to appropriately and accurately review the data. Moreover, the FDA, which sees trends in drug development long before the final products are used in routine clinical practice, highlighted the advent of a new era in which patients will be treated and taken care of on the basis of their own molecular profile. After the release of the final “Guidance for industry: pharmacogenomic data submissions” [3] in 2004 (the 2003 draft guidance was extensively discussed and many public comments have been incorporated in the final guidance), a rapid increase in pharmacogenetic- and other biomarker-driven drug development data submitted to the FDA was observed [4,5]. Assuming an average of 5-year delay from the time of submission to reaching the market, we indeed arrive at the 2009 upswing of publications on outcomes and cost in the field of personalized medicine. Considering that pharmacogenetic information was part of drug labels for a much longer period of time [6], it is still surprising that not much emphasis has been put on evaluating changes in clinical outcomes and determining cost associated with this field. Several possible explanations for the paucity of such data exist. Most of the early pharmacologically relevant biomarkers used in personalized medicine (or “pharmacogenetics”; the term “personalized medicine” was in fact introduced much later) were pharmacokinetic markers, such as variations in cytochrome P450 (CYP450) enzymes. In those early days, associations between a marker and a clinical outcome, particularly one that then could be affected, for example, via dose adjustment, were identified after the drug had already reached the market (a notable exception marks Her2/neu, a pharmacodynamic marker that was essential for the development of trastuzumab introduced to the US market in 1998). Because these markers were not discovered within the context of the actual drug development effort, the nature of the studies demonstrating the potential Copyright & 2013, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. Conflicts of interest: The author has indicated that he has no conflicts of interest with regard to the content of this article. * Address correspondence to: Felix W. Frueh, Opus Three LLC, Gaithersburg, MD 20878, USA. E-mail: [email protected]. 1098-3015/$36.00 – see front matter Copyright & 2013, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jval.2013.06.009 S28 VALUE IN HEALTH 16 (2013) S27–S31 clinical impact of the markers was markedly different from that of studies requiring a marker as an integral part of drug development (and its potentially required use as a diagnostic to guide therapy). To the most part, these studies were limited, with a small n, and not oriented toward hard clinical outcomes, but rather using soft or surrogate end points such as pharmacokinetic. Therefore, it was difficult to translate these markers into clinical practice, and in situations in which diagnostics measuring these markers had been developed, uptake was (and continues to be) slow: the lack of convincing studies that focus on relevant clinical outcomes poses a significant hurdle for the acceptance of personalized medicine in the clinic. Studies for newer markers that have been critical or even required for the (co-)approval of a drug associated with the marker of interest, however, are more rigorous, and the demonstration of clinical effectiveness and cost-effectiveness is significantly streamlined (see below). Therefore, many markers that are often cited in the context of personalized medicine have not been studied in pivotal trials, and although exploratory or smaller studies were conducted and may point toward clinical effectiveness and costeffectiveness, they were not convincing enough to regulators to, for example, update the label of a drug and requiring the use of a test or to payers to cover the payment of a test (or even require a test before authorizing the reimbursement for a drug). Moreover, in situations in which the FDA took the initiative to update the label of a particular drug, for example, warfarin [7], clopidogrel [8], and irinotecan [9], translation into clinical practice occurs slowly and reimbursement for these tests remains fragmented. More recently, in addition to tests that are directly associated with the use of a particular drug, developed either in conjunction of the drug or later [10], a third category of tests that are not associated with a particular drug therapy (although they can inform about appropriate therapies) has emerged. It is interesting to take a closer look at these three categories of personalized medicine tests, and the regulatory and reimbursement pattern they reveal: 1. Tests developed in association with a drug (drug-test codevelopment, e.g., Her2/neu for trastuzumab [11]). This category of tests benefits from the rigor of studies needed to bring the drug to the market, which bears several advantages: the regulatory pathway requires the test and the drug to be approved at the same time, reimbursement usually follows in line with the requirement of the test to demonstrate appropriate use of (or even eligibility to receive) the drug, and if the drug fails to gain approval, the test is likely not needed (at least not in this particular context). Moreover, in clinical practice, there is a significantly lower burden of informing and educating health care professionals about the benefit of the test because in this situation the test will likely be required to gain access to the drug. The onus of demonstrating the impact of the test is not only on the developer of the test but also on the manufacturer of the drug because of the vested interest in making the test available. This category of tests poses the least challenge with respect to demonstrating the effectiveness of a personalized medicine approach: it is inherent to the product (which is a personalized medicine product by definition), and clinical effectiveness and costeffectiveness data encompass both drug and test simultaneously. If approved by regulators, products in this category are also likely to be covered and reimbursed by payers. 2. Tests developed after the drug has reached the market. The fundamental difference between this and the aforementioned scenario is the state of clinical practice: although the previous example establishes clinical practice for both the test and the drug simultaneously, here the introduction of the test requires an adjustment or change in established clinical practice: this is much harder to achieve. Two different types of tests in this category exist: tests that are developed specifically for one drug product and tests that are of more general use. For the former, tests are developed as either improvements in existing tests already marketed (e.g., fluorescence in situ hybridization testing in lieu of immune histochemistry testing for trastuzumab) or new tests for drugs that were marketed without the need for a specific test (e.g., HLA-B*5701 testing for abacavir). The latter include tests such as assays for drug-metabolizing enzymes (e.g., CYP450s) that are relevant for the use of various drugs [12]. Although all these tests are developed after the drugs they are useful for, there are significant differences with respect to the level of evidence needed for them to be successfully introduced into clinical practice: clinical utility for tests that follow tests already on the market has, by definition, already been established. The characteristics of the new test (in particular sensitivity, specificity, and cost) determine its performance compared with that of its predecessor, and it can be judged relatively easily whether the cost-benefit profile of the new test is superior to that of the existing assay. For tests for which no predicate assays exist, this evaluation is more difficult and includes demonstration of clinical utility. In addition, costeffectiveness becomes a more critical component: the introduction of a new test will add cost and the demonstration that such additional cost to the system is warranted is necessary. This can be achieved by a significant improvement in outcomes, by a demonstration of overall savings to the system, or ideally by both. For example, HLA-B*5701 testing for abacavir has seen a rapid uptake: the high sensitivity and specificity of the test [13] enabled the use of abacavir in a much larger population owing to the ability of the test to detect patients who are at risk for a severe adverse event: the clinical benefit of the test clearly justified the additional expense of a test and likely also compensated for costs associated with the management of the adverse event, which may occur in patients for which abacavir poses a risk: clinical utility of HLA-B*5701 testing seemed apparent, and cost-effectiveness has been demonstrated [14] and also put in perspective by others later on [15]. In contrast, slow uptake was seen in situations in which the performance of the test was less clear, differences in outcomes harder to detect, and/or the information derived from the test more difficult to translate into precise clinical actions. It is interesting to note that in many of these latter cases, the clinical outcome—that is, the benefit of testing— may not be immediately apparent, but observed only over a period of months or even years (e.g., CYP2C19 testing for clopidogrel [16,17]) as opposed to a benefit that is much more rapidly discernible (e.g., HLA-B*5701 testing for abacavir). This delayed feedback makes it more difficult to design studies demonstrating the clinical utility of such tests not only due to long follow-up periods that may be needed but also due to the larger sample size required to demonstrate the correlation between the intervention (e.g., dose adjustment and change in therapy) and a more distant clinical outcome (e.g., prevention of a secondary event [16]). Consequently, it is also significantly more challenging to demonstrate cost-effectiveness in these situations. It is therefore not surprising that the incentives to develop such tests and to demonstrate their clinical and economic impact are misaligned with the interest in realizing an attractive return on investment because studies needed to demonstrate the clinical and economic impact can take several years and are costly. In many cases, it is difficult or even impossible to turn the development cost of such tests into profits, given the rates at which such tests are usually reimbursed. There are some situations, however, in which at least theoretically this approach appears to be more VALUE IN HEALTH 16 (2013) S27–S31 interesting: for example, if the decision impacts the selection of an expensive (usually branded) versus a cheaper drug (e.g., a generic) or significantly improves the clinical utility of a generic drug, the development of such tests may be feasible. This “genetics for generics” approach has been successfully demonstrated for the use of CYP450 2C9 and VKORC1 testing for warfarin [18] and is further described elsewhere [19,20]. 3. Tests not directly associated with a particular drug. The effectiveness of these tests is based on the assumption that the test can add significant information to the clinical decision making without, however, requiring the test for a particular intervention. Demonstrating clinical effectiveness can be challenging, but because many of these tests are addressing questions in clinical areas of high need and high cost (e.g., OncotypeDx [Genomic Health, Redwood City, CA] and Mammaprint [Agendia, Amsterdam, The Netherlands] to determine whether or not radiation therapy is needed for patients with breast cancer, or Foundation One (Foundation Medicine, Cambridge, MA) to determine which therapy might be most appropriate on the basis of the molecular profile of the cancer), the level of evidence accepted to use the tests in clinical practice is reduced: for example, it is not unreasonable to have such tests marketed without evidence derived from a prospective trial if convincing evidence can be obtained retrospectively (e.g., from information derived from the literature or with prospective validation of retrospective data) [21,22]. Because these tests are introduced in areas of high medical need and high costs associated with the treatments (or failure of treatments), the economic model for these tests is based on reducing health care costs if the decision about which treatment to choose or the identification of potential risk can be done early and unnecessary treatment or downstream complications can be prevented. Still, these technologies are new and the lack of prospective outcome-focused evidence does present an additional challenge, particularly for reimbursement decisions because payers often label such tests “experimental,” which usually results in a “no-coverage” assessment. As a result, reimbursement for these technologies has been challenging (further discussed below) and slow [23]. How can we accelerate generating the evidence that demonstrates clinical effectiveness and cost-effectiveness of these tests? Although regulators generally focus on the test by itself, payers want to know how effective the test is compared with alternative tests (if available) or interventions and preferably so in the real world, that is, the environment in which reimbursement decisions are actually being made. Ultimately, clinical outcomes are affected by more factors than the ones included in most clinical trials and the long-term benefit of an intervention may depend on criteria that may not be detected (or even excluded from detection) in trials such as adherence and adverse events. This puts developers of personalized medicine tests at crossroads for developing data needed to satisfy regulatory or reimbursement needs. Could such evidence be generated simultaneously? Even though significantly different, the two divergent demands overlap on several aspects and strategies to integrate one with the other are feasible. The FDA classifies tests (devices) into three categories on the basis of risk and intended use: class I are low risk, class II medium risk, and class III high risk. The rigor of review and evidence needed for regulatory clearance increases with the risk category of the device. Recently, the agency issued two documents aimed at providing guidance to industry to clarify the regulatory thinking around the evidence needed for the codevelopment of the drug and the test [24] and to elucidate “Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications” [25]. The S29 latter document is particularly interesting considering that it states that “Clinical testing methods for medical devices can include, when appropriate, randomized clinical trials in the appropriate target population, well-controlled investigations, partially controlled studies, studies and objective trials without matched controls, well-documented case histories conducted by qualified experts, reports of significant human experience, and testing on clinically derived human specimens (DNA, tissue, organ and cadaver studies)” (compare section 3.2 in Food and Drug Administration [25]). This direct citation from the Federal Register [26] points to the fact that more than one way exists to create the necessary evidence for regulatory approval of a device. Importantly, it indicates that randomized trials are not always needed, which opens a door to real-world, outcome-based approaches that may indeed be more aligned with the needs of payers. The Federal Register also mentions that “the evidence required may vary according to the characteristics of the device, its conditions of use, the existence and adequacy of warnings and other restrictions, and the extent of experience with its use” [26]. The goal of reimbursement decision making, however, depends less on risk but more on real-world clinical outcomes as well as the cost associated with reaching these outcomes: it aims at optimizing health outcomes within a defined insured population, considering all available treatment options and within the budgetary constraints of the payer. This results in a different set of parameters being considered by payers compared with regulators. For example, payers are more interested in comparative effectiveness information, cost offsets, absolute versus relative risk (e.g., a 20% reduction in risk in the entire population is of greater interest than a 20% reduction in 1% of the population), the impact on individuals compared with the impact on the population, and a number of other factors as detailed in Epstein et al. [27]. In addition, workplace productivity, absenteeism, quality of life, and other indirect cost metrics are considered by different types of payers (e.g., health plans, self-insured employers, government, and others) with different levels of importance. So, how can a regulatory focus aimed predominantly on safety and efficacy be combined with payers’ needs to address realworld effectiveness and cost? Recently, regulators indicated a heightened interest in comparative effectiveness data and realworld outcomes combined with an effort to increase postmarket safety data [28]. Considering such interest in light of new regulatory guidance on generating evidence for medical devices [25], this emerging regulatory framework creates a path for a convergence where the “dimension of reality” and the “dimension of comparativeness” meet in a middle area (Fig. 1) in which efforts that parallel regulatory and reimbursement needs are feasible. This area can be defined, for example, by real-world trials that investigate new medical products or interventions versus any alternative treatment. In the case of personalized medicine, information may be shifted more toward the effectiveness side where randomized controlled trials may not be required (or may not be feasible under some circumstances) and casecontrol or cohort studies may be deemed appropriate. This shift will, however, at least initially, occur on a case-by-case basis and depends on various factors, including the ones outlined above such as a rigorous assessment of risk. Nevertheless, it is now reasonable to generate strategies for gaining regulatory approval moving from a currently static to an increasingly dynamic paradigm (Fig. 2), which addresses the needs of payers at the same time. This can have important consequences for the implementation of personalized medicine into clinical practice. In contrast to such a synergistic convergence, some diagnostic companies started to look for alternative ways to establish the evidence needed for regulatory as well as reimbursement decisions. This may be driven by the uncertainty about specific regulation and reimbursement potential and has led to radically S30 VALUE IN HEALTH 16 (2013) S27–S31 Fig. 1 – Path of Convergence created by the emerging regulatory framework. The dimension of reality and the dimension of comparativeness meet where alternative treatments are compared with new interventions and hard clinical outcomes are measured in a rigorous fashion. Reprinted from the Pharmaceutical Forum - Working Group on Relative Effectiveness, Availability of data to conduct relative effectiveness assessments, with permission from the European Commission. different business models: for example, the development and sale of “laboratory developed tests” has become more frequent owing to the perception of no or limited regulatory oversight for such tests. In fact, there appears to be a trend toward these types Assessor body Evidence focus of tests from not only a regulatory viewpoint but also a reimbursement perspective. It allows manufacturers to get paid more directly (including via the patient’s insurance), but it often requires the creation of a billing and reimbursement department Current paradigm is static Future paradigm is dynamic Approval Approval Regulators Payers Absolute (safety and) efficacy Clinical and cost effectiveness • Quality, safety, efficacy • Benefit-risk profile • Relative efficacy/effectiveness • Cost vs. health benefit • Budget impact Regulators Payers New relative safety and efficacy assessment, including real-world effectiveness assessment • Quality, safety, efficacy • Benefit-risk profile • Cost vs. health benefit • Budget impact • Relative efficacy/effectiveness Studies / Data • Emphasis on RCT • Placebo-controlled • Active controlled RCT • Observational studies • Cost effectiveness / utility analyses • Budget impact analyses • Emphasis on RCT • Placebo-controlled • Cost effectiveness / utility analyses • Budget impact analysis • Active controlled RCT • Adaptive Ph III-IV trials • Observational studies • Meta analysis Fig. 2 – Shift in strategies to generate (clinical) evidence that is useful for both, regulatory and reimbursement needs. Notably, a shift from static, to a more dynamic paradigm of evidence generation is observed. Data from Eichler et al. [29]. VALUE IN HEALTH 16 (2013) S27–S31 to directly negotiate and manage the reimbursement process with payers including the management of appeals in the case of a no-coverage decision. By choosing this route of entering the market, manufacturers can reach clinical practice faster and are more likely to stay in control of pricing. Nevertheless, it prevents the tests from being sold to third parties, which can be a severe limitation, and not all manufacturers are willing to establish an operation that includes noncore functions, such as sales force and billing and reimbursement divisions, that may be needed to create, expand, and maintain a solid presence in the market. It is reasonable to assume that in the future, clinical effectiveness and cost-effectiveness questions will be addressed earlier in the development of personalized medicines. The answer to the question about where and how studies demonstrating clinical benefit combined with cost-effectiveness are being conducted is evolving, and new, innovative approaches are being explored to combine regulatory and reimbursement needs. The evolving and still relatively uncertain regulatory environment as well as the challenges posed by the reimbursement system can negatively impact the development of new personalized medicine products: more clarity is needed from regulators and payers explaining their expectations for data and evidence in approval and coverage decisions. Nevertheless, manufacturers must accept that without outcomes and economic information, their products will be difficult to introduce into clinical practice: health economics and outcomes research will be the key to opening this market. Source of financial support: ISPOR provided a modest honorarium. R EF E R EN CE S [1] National Center for Biotechnology Information. Available from: http:// www.ncbi.nlm.nih.gov/pubmed. [Accessed October 26, 2012]. [2] Lesko LJ, Woodcock J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002;2:20–4. [3] Food and Drug Administration. FDA guidance: pharmacogenomic data submissions. Available from: http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm126957.pdf. [Accessed October 31, 2012]. [4] Goodsaid FM, Amur S, Aubrecht J, et al. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov 2010;9:435–45. [5] Goodsaid F, Frueh FW. Implementing the U.S. FDA guidance on pharmacogenomic data submissions. Environ Mol Mutagen 2007;48: 354–8. [6] Frueh FW, Amur S, Mummaneni P, et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 2008;28:992–8. [7] Access Data. Prescribing information for COUMADIN® tablets. Available from: http://www.accessdata.fda.gov/drugsatfda_ docs/label/2010/009218s108lbl.pdf. [Accessed October 31, 2012]. [8] Access Data. Highlights of prescribing information for PLAVIX. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/ 020839s052lbl.pdf. [Accessed October 31, 2012]. [9] Access Data. Prescribing Information for Camptosar® (irinotecan hydrochloride) injection. Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2006/020571s030lbl.pdf. [Accessed October 31, 2012]. S31 [10] Towse A, Garrison, LP. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value Health 2013;16(Suppl.):S39–43. [11] Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737–44. [12] Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics 2013;13: 1–11. [13] Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568–79. [14] Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004;14:335–42. [15] Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025–33. [16] CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39. [17] Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 2009;10:1799–817. [18] Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010;55:2804–12. [19] Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Costeffectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 2012;32:323–32. [20] Genome Web. Medco’s new idea: PGx program for generics to dispense ‘smarter’ treatments and increase savings. Available from: http://www. genomeweb.com/dxpgx/ medcos-new-idea-pgx-program-generics-dispense-smarter-treatmentsand-increase-sa. [Accessed October 30, 2012]. [21] Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005;11(24, Pt 1):8623–31. [22] Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007;53:1084–91. [23] Gustavsen G, Phillips K, Pothier K. The reimbursement landscape for novel diagnostics: current limitations, real-world impact, and proposed solutions. Available from: http://www.healthadvances.com/pdf/ novel_diag_reimbursement.pdf. [Accessed August 19, 2013]. [24] Food and Drug Administration. FDA draft guidance: in vitro companion diagnostic devices. Available from: http://www.fda.gov/downloads/ MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ UCM262327.pdf. [Accessed October 31, 2012]. [25] Food and Drug Administration. FDA guidance: factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications. Available from: http://www.fda. gov/downloads/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/UCM296379.pdf. [Accessed October 31, 2012]. [26] 21CFR860.7. Code of federal regulations title 21. Available from: http:// www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm? FR=860.7. [Accessed October 31, 2012]. [27] Epstein RS, Frueh FW, Geren D, et al. Payer perspectives on pharmacogenomics testing and drug development. Pharmacogenomics 2009;10:149–51. [28] Giffin RB, Woodcock J. Comparative effectiveness research: who will do the studies? Health Aff (Millwood) 2010;29:2075–81. [29] Eichler HG, Bloechl-Daum B, Abadie E, et al. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov 2010;9:277–91.